User profiles for Sorin Rugina
 | Sorin RuginaScoala Doctorala de Medicina-Universitatea Ovidius din Constanta/Doctoral School of … Verified email at univ-ovidius.ro Cited by 6345 |
[HTML][HTML] HLA-B* 5701 screening for hypersensitivity to abacavir
…, J Tomažič, E Jägel-Guedes, S Rugina… - … England Journal of …, 2008 - Mass Medical Soc
Background Hypersensitivity reaction to abacavir is strongly associated with the presence of
the HLA-B*5701 allele. This study was designed to establish the effectiveness of …
the HLA-B*5701 allele. This study was designed to establish the effectiveness of …
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3 …
…, F Constandis, SM Erscoiu, LJ Prisacariu, S Rugina… - The lancet HIV, 2018 - thelancet.com
Background Doravirine is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …
a pharmacokinetic profile supporting once-daily dosing, and potent in-vitro activity against …
Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy
…, KH Han, A Mohsin, M Rodriguez–Torres, S Rugina… - Gastroenterology, 2014 - Elsevier
Background & Aims Thrombocytopenia is common among patients with hepatitis C virus (HCV)
infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-…
infection and advanced fibrosis or cirrhosis, limiting initiation and dose of peginterferon-…
Forty‐eight‐week efficacy and safety and early CNS tolerability of doravirine (MK‐1439), a novel NNRTI, with TDF/FTC in ART‐naive HIV‐positive patients
…, A Keikawus, C Hoffmann, S Rugina… - Journal of the …, 2014 - Wiley Online Library
Introduction Doravirine (DOR) is an investigational NNRTI (aka MK‐1439) that retains activity
against common NNRTI‐resistant mutants. We have previously reported the Part 1 results …
against common NNRTI‐resistant mutants. We have previously reported the Part 1 results …
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non …
…, F Constandis, SM Erscoiu, LJ Prisacariu, S Rugina… - The lancet HIV, 2020 - thelancet.com
Background Doravirine is a novel, non-nucleoside reverse transcriptase inhibitor that has
shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults …
shown non-inferior efficacy to ritonavir-boosted darunavir, with a superior lipid profile, in adults …
[HTML][HTML] Carbapenem-Resistant Klebsiella pneumoniae Associated with COVID-19
…, DS Carp, A Dumitrescu, R Mitan, R Lesanu, S Rugina - Antibiotics, 2021 - mdpi.com
Infections with carbapenem-resistant Enterobacteriaceae are emerging as an important
challenge in healthcare settings. Currently, carbapenem-resistant Klebsiella pneumoniae (CRKP…
challenge in healthcare settings. Currently, carbapenem-resistant Klebsiella pneumoniae (CRKP…
Pharmacokinetics, safety and efficacy of darunavir/ritonavir in treatment-experienced children and adolescents
S Blanche, R Bologna, P Cahn, S Rugina, P Flynn… - Aids, 2009 - journals.lww.com
Objective: To assess pharmacokinetics, safety and efficacy of darunavir/ritonavir (DRV/r)
and optimized background regimen in treatment-experienced patients (6–17 years). Design: …
and optimized background regimen in treatment-experienced patients (6–17 years). Design: …
Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE …
…, F Constandis, SM Erscoiu, LJ Prisacariu, S Rugina… - The Lancet …, 2024 - thelancet.com
Background In two phase 3 trials for first-line therapy in adults with HIV-1, doravirine showed
non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and …
non-inferior efficacy, a favourable safety profile, and a superior lipid profile to darunavir and …
Doravirine dose selection and 96-week safety and efficacy versus efavirenz in antiretroviral therapy-naive adults with HIV-1 infection in a Phase IIb trial
…, DE Smith, J Portilla, S Rugina… - Antiviral …, 2019 - journals.sagepub.com
Background The safety and efficacy of doravirine were compared with that of efavirenz as
initial treatment of adults living with HIV-1 infection (NCT01632345). Methods A Phase IIb …
initial treatment of adults living with HIV-1 infection (NCT01632345). Methods A Phase IIb …
Predictors of carbapenem-resistant Enterobacteriaceae (CRE) strains in patients with COVID-19 in the ICU ward: a retrospective case–control study
…, C Nemet, S Voidăzan, S Rugină… - Journal of …, 2022 - journals.sagepub.com
Objective To identify carbapenem-resistant Enterobacteriaceae (CRE) in patients infected
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) and to …
with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) and to …